Please assess the completion status of the following clinical trial:

Trial Title: AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and written informed consent~* Age 18 year or older~* Metastatic or incurable locally advanced lobular breast cancer with confirmation of the lobular histology and E-cadherin loss on a biopsy of a metastatic lesion.~* Metastatic lesion accessible for histological biopsies~* Evidence of progression of disease~* A maximum of two lines of palliative chemotherapy~* WHO performance status of 0 or 1~* Evaluable disease or measurable according to RECIST 1.1~Exclusion Criteria:~* Leptomeningeal disease localization~* History of having received other anticancer therapies within 2 weeks of start of the study drug~* History of immunodeficiency, autoimmune disease, conditions requiring immunosuppression~* Prior treatment with immune checkpoint blockade~* Live vaccine within 2 weeks prior to start of study~* Active other cancer~* Active hepatitis B

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carboplatin/Atezolizumab (Type: EXPERIMENTAL): Carboplatin AUC=1.5, weekly schedule, maximum 12 administrations Atezolizumab, 1200 mg flat dose, 3-weekly schedule, starting after two administrations of carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).